HCPCS Code J2777: Injection, Faricimab-svoa, 0.1 mg

Learn about the HCPCS code J2777 for injection, faricimab-svoa, 0.1 mg, through this short guide.

## **What is the HCPCS code J2777 for?** The HCPCS code J2777 is a J code. J codes are a group of codes that mostly designate injected medication. In the case of J2777, the injection is of faricimab-svoa (sometimes referred to by the brand name Vabysmo), specifically a 0.1 mg dosage. This is a prescribed injected medication of a pharmacologic agent. Healthcare providers inject patients in their eye with this medicine to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME) caused by (chemical-induced) diabetes mellitus, macular edema following retinal vein occlusion (RVO), exudative age-related macular degeneration (with active choroidal neovascularization). Patients taking this treatment will have to take it several times after the initial dose, usually every 4 weeks (or 28 days), for at least 4 doses. What this medicine does is prevent abnormal blood vessel growth and leakage in the eye by blocking vascular endothelial growth factors and Ang-2 to prevent vision loss.

## **Documentation requirements for J2777** As with any procedure, especially involving injecting drugs into patients, it's important to document the following before you file for a claim that includes this code: - The full name of the personnel who administered the injection + their credentials - The name and address of the facility where the injection was administered - The full name of the patient - The date and time of the drug administration by injection, including the drug code description and other relevant information - Patient records showing they have been diagnosed with wet age-related macular degeneration (AMD), diabetic macular edema (DME) caused by (chemical-induced) diabetes mellitus, or macular edema following retinal vein occlusion (RVO) to support medical necessity - Blood test results and imaging tests that show the status of the affected eye, especially the severity of the problem - The exact dosage and route (0.1 mg is equal to 1 unit)

## **Billing requirements for J2777** Besides the documentation requirements above, please note the following billing requirements for this HCPCS code: - They must reflect the dosage given over the course of the treatment. - Use either of two modifiers: JW if there's unused medication in a vial (wastage), or JZ if there's no unused medication. - Use modifiers RT or LT. The former is for the right eye, the latter for the left. Make sure to use the proper ICD code, too. There's a number of codes you can use, especially for diabetic retinopathy. For diabetic retinopathy, you have ICD codes for proliferative diabetic retinopathy, severe nonproliferative diabetic retinopathy, moderate nonproliferative diabetic retinopathy, mild nonproliferative diabetic retinopathy, and unspecified diabetic retinopathy. If they're confirmed to have diabetes, please also use ICD codes for designating diabetes and other specified diabetes mellitus, when applicable. You must also use CPT code 67028 since this is an intravitreal injection.

## **Other similar codes** - **J3590** – Unclassified biologics - **J2778** – Injection, ranibizumab, 0.1 mg - **Q5128** – Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg - **J0178** – Injection, aflibercept, 1 mg

Frequently asked questions

They shouldn't drive or use machinery after taking this until their eye recovers.

Eye infections, swelling around the eye, retinal detachment, eye inflammation, intraocular pressure. These require immediate attention. Severe but rare complications include stroke and heart attacks.

Female patients need to inform the ophthalmologist if they're pregnant or plan to get pregnant, or if they're currently breastfeeding or plan to breastfeed a baby. Patients in general have to inform the eye doctor about any medications they're taking and any allergies they might have.